Citation Impact
Citing Papers
Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations
2015
Intrinsic Resistance to MEK Inhibition through BET Protein–Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer
2019
HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF -Mutant Colorectal Cancer by Downregulation of c-FLIPL
2015
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017 Standout
Illuminating the dark phosphoproteome
2019
Colorectal cancer statistics, 2020
2020 Standout
Racial disparity in distant recurrence‐free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials
2022
Colorectal cancer statistics, 2023
2023 Standout
Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner
2018 StandoutNobel
Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer
2019 StandoutNobel
Mutant-selective degradation by BRAF-targeting PROTACs
2021
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Using tumour phylogenetics to identify the roots of metastasis in humans
2015
A view on drug resistance in cancer
2019 StandoutNature
From tumour heterogeneity to advances in precision treatment of colorectal cancer
2016
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Hepatocellular carcinoma
2016 Standout
COPD Guidelines: A Review of the 2018 GOLD Report
2018 Standout
Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer
2015
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
2020 Standout
Wnt signaling in cancer
2016 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
2019 Standout
The immune contexture in cancer prognosis and treatment
2017 Standout
Cancer stem cells revisited
2017 Standout
RAS-targeted therapies: is the undruggable drugged?
2020
Colorectal cancer
2019 Standout
Cancer-associated cachexia
2018 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Targeting RAS–ERK signalling in cancer: promises and challenges
2014
Histology-agnostic drug development — considering issues beyond the tissue
2020
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Mesenchymal Cells in Colon Cancer
2017
Current and future biomarkers in colorectal cancer
2017
A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis
2016
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Cancer-associated fibroblasts in the single-cell era
2022
Current understanding of the human microbiome
2018 Standout
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
2020 Standout
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
EMT: 2016
2016 Standout
Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
2015
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
2012 Standout
Gastric cancer
2020 Standout
A framework for understanding and targeting residual disease in oncogene-driven solid cancers
2016
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
The PI3K Pathway in Human Disease
2017 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma
2018
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Mining electronic health records: towards better research applications and clinical care
2012 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence
2018
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Young-onset colorectal cancer
2023
Fusobacterium nucleatum — symbiont, opportunist and oncobacterium
2018 Standout
Robust Replication of Genotype-Phenotype Associations across Multiple Diseases in an Electronic Medical Record
2010
Transforming targeted cancer therapy with PROTACs: A forward-looking perspective
2021
Biomarker-driven and molecular targeted therapies for colorectal cancers
2017
Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement
2019 Standout
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
2015
Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics
2016
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA
2018
Breast Cancer Statistics, 2022
2022 Standout
Metastasis-Initiating Cells and Ecosystems
2021
Bladder Cancer
2020 Standout
Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer
2019
Metastasis as an evolutionary process
2016 Science
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
2015
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Antibody-Drug Conjugates in Urothelial Carcinomas
2020
IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers
2019
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
2018
Constraints in cancer evolution
2017
Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform
2014
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs
2019 Standout
Diagnosis and Treatment of Metastatic Colorectal Cancer
2021
Works of Rona Yaeger being referenced
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition
2017
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
2021
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
2014
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients
2015
Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations
2017
Lineage Reversion Drives WNT Independence in Intestinal Cancer
2020
Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer
2020
BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy
2012
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
2017
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
2017 Nature
Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease
2016
False-Positive Elevations of Carcinoembryonic Antigen in Patients With a History of Resected Colorectal Cancer
2014
BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.
2018
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
2019
A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
2018
PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases
2017
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer
2014
Comparing Genetic Ancestry and Self-Described Race in African Americans Born in the United States and in Africa
2008
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
2014
Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer
2015
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)
2016
BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer
2019
Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).
2016
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
2014
Impact of somatic mutations on patterns of metastasis in colorectal cancer.
2015